abstract |
The present invention relates to genetically modified hybridomas, myeloma and B cells. The present invention also relates to utilizing genetically modified hybridomas, myeloma and B cells in a method of making monoclonal antibodies. The present invention also provides a population of hybridomas and B cells that can be used to produce the monoclonal antibody of interest. In one embodiment, the hybridoma cell population of the invention has more than 15% of the cells in the population express a monoclonal antibody bound to the cell surface. |